Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159625 | 1.00 | HDAC1 (0.61) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL6157861 | 1.00 | HDAC1 (0.61) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL29984836 | 0.97 | HDAC1 (0.60) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL13561436 | 0.97 | HDAC1 (0.60) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL28764653 | 0.97 | HDAC1 (0.60) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL30711879 | 0.97 | HDAC1 (0.60) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL392598 | 0.92 | HDAC1 (0.57) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL377964 | 0.92 | HDAC1 (0.57) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL15982313 | 0.92 | HDAC1 (0.57) | HDAC1HDAC2IDO1MDM4TP53 | |
| SCHEMBL29555721 | 0.92 | HDAC1 (0.57) | HDAC1HDAC2IDO1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1504094-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1504109-A1 | METHOD FOR THE PRODUCTION OF LACTIC ACID OR A SALT THEREOF BY SIMULTANEOUS SACCHARIFICATION AND FERMENTATION OF STARCH | Purac Biochem BV (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003095475-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003095659-A1 | METHOD FOR THE PRODUCTION OF LACTIC ACID OR A SALT THEREOF BY SIMULTANEOUS SACCHARIFICATION AND FERMENTATION OF STARCH | PURAC BIOCHEM B.V. (NL) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | MMP3, MMP25, MMP11 | HDAC1 1031/4885HDAC2 2428/4885IDO1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.